Tag Archives: American Lung Association

105770502

American Lung Association adds 4 female leaders

The American Lung Association in Arizona Women’s Cabinet has added four new members. They join the volunteer women’s cabinet that provides executive leadership for LUNG FORCE. LUNG FORCE is the American Lung Association’s national health education movement with a singular mission to unite women to stand together against lung cancer and for lung health.

“We are thrilled to welcome this strong slate of members to the inaugural Women’s Cabinet,” Julie Reid, American Lung Association in Arizona Executive Director said. “Their diverse talents will help the American Lung Association in Arizona continue to grow as a leader in the lung health and lung research community.”

The new Women’s Cabinet members are:

Jane A. White, PT, MPT, DHSc

Jane A. White, PT, MPT, DHSc, is a physical therapist who currently serves as the Senior Director of Integrative Services at Cancer Treatment Centers of America in Goodyear, Arizona.  Throughout her physical therapy career, Dr. White has held positions in a variety of rehab settings but found her true calling as an advocate for holistic, patient-centered care.

Dr. White graduated with a Bachelor of Arts degree from Felician College in Lodi, New Jersey and later earned a Master of Physical Therapy degree from The Richard Stockton College of New Jersey.  In 2013, she received a Doctor of Health Sciences degree from A.T. Still University, in Mesa, Arizona.

Amber Porter, BSN

Amber Porter is a family nurse practitioner at Banner University Medical Center who specializes in Cystic Fibrosis and Bronchiectasis with an emphasis on preventing hospitalization through early intervention and education, Pulmonary hypertension management, Alpha 1 Antitrypsin and Pulmonary Fibrosis. She has also been involved in clinical research for over 16 years in many capacities, most recently being a sub investigator on many Advanced Lung Disease trials. She received her BSN and Masters of Science in Nursing from Grand Canyon University in Phoenix.

Karen Swanson, D.O.

Dr. Swanson is a Board Certified Pulmonologist in Scottsdale, Arizona. She has also been actively involved in medical education and was the program director of the Pulmonary and Critical Care Medicine Fellowship at Mayo Clinic’s campus in Rochester, Minnesota, until transferring to Arizona in 2013. She is currently the chair of the Division of Pulmonary and Critical Care Medicine at Mayo Clinic’s campus in Phoenix/Scottsdale, Arizona. Dr. Swanson graduated with her D.O. from the College of Osteopathic Medicine of the Pacific, Western University of Health Sciences. She later completed her Internal Medicine Internship and Pulmonary/Critical Care Medicine Fellowship at the Mayo Graduate School of Medicine, Mayo Clinic College of Medicine.

Carla Rotering, M.D., M.A.

Carla J. Rotering, MD, is a physician with an extensive medical practice and education who is serving as Vice President of Physician Services with the Leebov Golde Group. She practices Pulmonary Medicine and is Medical Director of Respiratory and Pulmonary Rehabilitation at both Banner Thunderbird Medical Center and White Mountains Regional Medical Center in Arizona. She is the former Chief of Staff and currently serves as Chair of the Physician Health and Wellness Committee at Banner Thunderbird Medical Center.  Dr. Rotering earned her medical degree from the University of North Dakota School of Medicine, and completed her Internal Medicine Residency and Pulmonary Fellowship in Phoenix, AZ.  She also holds a Master’s degree in Spiritual Psychology from the University of Santa Monica with an emphasis on consciousness, health and healing.

cancer

TGen finds clue to stop spread of lung cancer

Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute (TGen).

The hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14) are proteins associated with the potential spread of non-small cell lung cancer (NSCLC), according to the TGen study published online April 8 by the scientific journal Clinical & Experimental Metastasis.

NSCLC represents more than 85 percent of all lung cancers, which this year will kill an estimated 159,000 Americans, making it by far the leading cause of cancer-related death. It has a 5-year survival rate less than 10 percent.

The invasive and metastatic nature of NSCLC contributes to this high mortality rate, and so finding the cause of this potential to spread is key to helping patients survive.

Therapies targeting MET and FN14 are in clinical development, which could lead to treatments that could help halt or slow the spread of this lung cancer.

“As the metastatic phenotype is a major cause of lung cancer mortality, understanding and potentially targeting these pathways may reduce the high mortality rate in advanced lung cancer,” said Dr. Timothy Whitsett, an Assistant Professor in TGen’s Cancer and Cell Biology Division, and the study’s lead author.

Significantly, the TGen study found that MET and FN14 were elevated in metastatic tumors compared to primary lung tumors and suppression of MET activation or FN14 expression reduced tumor cell invasion.

“The elevation of these receptors in metastatic disease opens the possibility for therapeutic intervention,” said Dr. Nhan Tran, an Associate Professor in TGen’s Cancer and Cell Biology Division, and the study’s senior author.

Dr. Glen Weiss, Co-Unit Head of TGen’s Lung Cancer Research Laboratory and Director of Clinical Research at Cancer Treatment Centers of America at Western Regional Medical Center, said, “This study identifies some targets that already have drugs in clinical trials, and helps put them into context for what might be a rational drug development approach for the treatment of this deadly cancer.”

Other institutes that assisted with this study are: the University of Arizona; St. Joseph’s Hospital and Medical Center; and Humboldt Medical Specialists.

The study, FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion, was funded by the National Institutes of Health, and grants from the St. Joseph’s Foundation and the American Lung Association.